| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2165 | Fotocaine | Novel Photochromic Ion Channel Blocker |
|
| DCC2166 | Fotyr-amp | Novel NO-donating antimicrobial peptide, exhibiting Staphylococcus aureus and Escherichia coli biofilm dispersion and eradication, and potent antibacterial activities in vitro |
|
| DCC2167 | Fpr-agonist-17b | Novel agonist of the formyl peptide receptor (FPR), protecting against myocardial ischaemia-reperfusion injury in mice |
|
| DCC2168 | Fr-139317 | Selective ET(A) receptor antagonist |
|
| DCC2169 | Fr171456 | Natural specific inhibitor of mammalian NSDHL and yeast Erg26p, inhibiting an artificial Hepatitis C viral replicon, and showung broad antifungal activity |
|
| DCC2170 | Fr181877 | Nonprostanoid PGI2 agonist |
|
| DCC2171 | Fr-190809 | Potent and nonadrenotoxic ACAT inhibitor |
|
| DCC2172 | Fr-190997 | Novel Nonpeptide Bradykinin B2-Receptor Partial Agonist |
|
| DCC2173 | Fr194921 | Potent, selective, and orally active antagonist for central adenosine A1 receptors |
|
| DCC2174 | Frf-01-116 | Novel Potent and Selective Covalent Inhibitor of KRAS G12C |
|
| DCC2175 | Fropofol | Potent ligand for a protein site governed largely by van der Waals interactions, producing excitatory activity in tadpoles and mice; also antagonizing propofol-induced hypnosis |
|
| DCC2176 | Fs2921 | Novel N-Methyl-d-aspartate receptor (NMDAR) positive allosteric modulator (PAM) with potential antidepressant effects |
|
| DCC2177 | Fs-694 | Novel highly potent and selective inhibitor (type 1.5 binding mode) of MAPK14 [IC50 = 0.2 nM (ELISA, cell free); KD = 1.5 nM (DiscoverX)] |
|
| DCC2178 | Ftbu-1 | Novel Anabolic Selective Androgen Receptor Modulator (SARM) |
|
| DCC2179 | Fti-2628 | Novel inhibitor of protein farnesyltransferase (FT), inhibiting the growth of P. falciparum in red blood cells and suppressing parasitemia |
|
| DCC2180 | Fti-277 Tfa Salt | Farnesyltransferase inhibitor, inhibiting both H- and K-Ras oncogenic signaling |
|
| DCC2181 | Fto-04 | Novel fat mass- and obesity-associated protein (FTO) inhibitor, preventing neurosphere formation in patient-derived glioblastoma stem cells (GSCs) without inhibiting the growth of healthy neural stem cell-derived neurospheres |
|
| DCC2182 | Ftsz Probe (r)-5 | Novel specific high-affinity fluorescent probe for FtsZ antibacterial inhibitor |
|
| DCC2183 | Fty720-c2 | FTY720 analog as novel potent stimulator of the activity of the protein phosphatase 2A (PP2A) |
|
| DCC2184 | Fty720-mitoxy | FTY720 analog as novel stimulator of the activity of the protein phosphatase 2A (PP2A), targeting mitochondria |
|
| DCC2185 | Fumaropimaric Acid | Direct inhibitor of the p53 transactivation domain from binding to replication protein A |
|
| DCC2186 | Fumarprotocetraric Acid | Natural antimicrobial agent, showing neuroprotective, expectorant, and antioxidant activities |
|
| DCC2187 | Fumitremorgin C | Chemosensitizing agent, selectively reversing BCRP-mediated multidrug resistance to mitoxantrone, doxorubicin, and topotecan |
|
| DCC2188 | Fur-2-oyl-leu-gly-nh2 | Highly potent dopamine D2 modulator |
|
| DCC2189 | Furaltadone Hydrochloride | Anti-bacterial metabolite of Nitrofuran |
|
| DCC2190 | Furaprevir | Novel potent Hepatitis C virus (HCV) NS3/4A protease inhibitor |
|
| DCC2191 | Furathiocarb | Insecticide, acting as an EC 3.1.1.7 (acetylcholinesterase) inhibitor |
|
| DCC2192 | Fusarubin | Natural neuroprotective agent on glutamate-mediated HT22 cell death, controlling the amount of ubiquinone, up-regulating p21 expression in a p53-dependent manner, decreasing Akt phosphorylation and resulting in increased Fas ligand production and caspase- |
|
| DCC2193 | Fw1256 | Novel slow-releasing hydrogen sulfide (H2S) donor, inhibiting NF-κB activity and inducing cell apoptosis |
|
| DCC2194 | Fxia-6f | Novel highly potent Factor XIa inhibitor with selectivity against most of the relevant serine proteases |
|
